Source: Sharecast
Hikma said group revenue had risen 6% to $1.66bn in the six months ended 30 June, buoyed by double-digit growth in injectables, most notably in Europe, but also said operating profits had fallen 26% to $259m, impacted by a legal settlement and changes in product mix.
Core operating profits declined 7% to $373m, and core underlying earnings slipped 5% to $429m as margins came under pressure across segments, with injectables posting a 30.0% core operating margin and Hikma Rx falling to 17.6%. Branded medicines fared better, with a 30.4% margin and a 3% rise in core operating profit.
Hikma also said cash flow from operations had slumped 19% to $161m, though profit attributable to shareholders rose 5% to $238m. Basic earnings per share increased 6% to USD 108 cents, and interim dividends were hiked 12% to USD 36 cents.
Chief executive Riad Mishlawi said: "In the first half of 2025, the strategic changes and renewed focus we put in place have started to deliver tangible results. We achieved strong revenue growth and built solid momentum across the business. While core operating profit was lower due to a strong comparator in 2024 and a change in product mix, we expect a return to growth in the second half and are pleased to reiterate our full-year 2025 guidance for the group."
As of 0850 BST, Hikma shares had sunk 6.95% to 1,753p.
Reporting by Iain Gilbert at Sharecast.com
